BioForm Medical to Present At the Maxim Group Growth Conference

BioForm Medical to Present At the Maxim Group Growth Conference - Yahoo! Finance.gnwlistitemmarginbottom {margin-bottom: 10.0px} .gnwtablebottommargin {margin-bottom: 10.0px} .gnwcellpaddingleft0 {padding-left: 0.0px} .gnwverticalaligntop {vertical-align: top} .gnwtextaligncenter {text-align: center} .gnwcellparagraphmargin {margin-bottom: 0px; margin-top: 0px} .gnwverticalalignbottom {vertical-align: bottom} .gnwwhitespacenowrap {white-space: nowrap} .gnwtextalignright {text-align: right} .gnwcellpaddingright0 {padding-right: 0.0px} .gnwunderlinestyle {text-decoration: underline} .gnwtextalignleft {text-align: left} .gnw_heading {font: 16px Arial; text-align: center} .gnw_subhead {font: 12px Arial; text-align: center} .gnw_colhead {font: 12px Arial; text-align: center} .gnw_colhead_uline {font: 12px Arial; text-align: center; border-bottom: solid black 1.0pt;} .gnw_colhead_dline {font: 12px Arial; text-align: center; border-bottom: double black 2.5pt;} .gnw_label {font: 12px Arial; vertical-align: bottom; text-align: left } .gnw_label_uline {font: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: solid black 1.0pt;} .gnw_label_uline_i10 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i15 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i20 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i25 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i30 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_dline {font: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: double black 2.5pt;} .gnw_label_i10 {font: 12px Arial; vertical-align: bottom; text-align: left; padding-left: 10.0px;} .gnw_label_i15 {font: 12px Arial; vertical-align: bottom; text-align: left; padding-l...
Click here to read the whole Article (external link)

BioForm Medical, Inc. CEO Interview: Steven L. Bastar

67 WALL STREET, New York - September 22, 2009 - The Wall Street Transcript has just published its Medical Devices Report offering a timely review of the sector to serious investors and industry executives. This 41 page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online. Topics covered: Developments in the Industry -- New Devices -- Negative Price Pressure -- Inject Mix -- Hospital Capital Spending Behavior -- Growth -- Rate of Growth Reliability -- Execution of Management -- Clinical Trials -- The Next Big Thing -- Innovation -- Acquisition -- Loss -- Major Turnarounds -- Productive Work Force -- Medication Adherence -- Undervaluation -- Improvement in Earnings -- Price Sensitivity -- Weakening Dollar -- Winning Market Share -- Significant Share Gains -- Profitability -- Regulatory Standard -- Opportunities -- Licensing Opportunities -- Collective Experience -- Drug Approvals -- Growth in Revenue -- Measuring Success -- Profit Margins Companies include: Medtronic (MDT); Boston Scientific (BSX); Greatbatch (GB); Vascular Solutions (VASC); AngioDynamics (ANGO); St. Jude Medical (STJ); Edwards Lifesciences (EW); Stryker (SYK); Zimmer Holdings (ZMH); Abbott Laboratories (ABT); Johnson and Johnson (JNJ); Baxter International (BAX); Thoratec (THOR); HeartWare (HTWR); Hill-Rom Holdings (HRC); Accuray (ARAY); Smith and Nephew (SN.L); Wright Medical (WMGI); NuVasive (NUVA); TranS1 (TSON); Becton, Dickinson (BDX); C.R. Bard (BCR); Covidien (COV); C...
Click here to read the whole Article (external link)

BIOFORM MEDICAL INC Files SEC form 10-K, Annual Report

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of the financial condition and results of our operations should be read together with our financial statements and related notes elsewhere in this Form 10-K. In addition to historical information, this discussion and analysis contains forward-looking statements reflecting our current expectations that involve risks, uncertainties and assumptions. Actual results and the timing of events may differ materially from those contained in these forward-looking statements due to a number of factors, including those discussed in the section entitled "Risk Factors" and elsewhere in this document. Overview We are a medical aesthetics company focused on developing and commercializing products that are used by physicians to enhance the appearance of their patients. We were incorporated in Delaware in 1999 and commenced operations in 2000. From 2001 to 2003, we received certain U.S. and international regulatory clearances and approvals for, and engaged in commercial sales of, RADIESSE® and COAPTITE®. We obtained FDA pre-market approval, or PMA, for our key commercial application of RADIESSE® in December 2006. Our core product is RADIESSE®, an injectable dermal filler which is designed to provide long-lasting, cost-effective and safe aesthetic benefits for patients. We have also developed and commercialized COAPTITE®, an FDA approved tissue-bulking agent, which is marketed through our distribution agreement with Boston Scientific for use in the treatment of stress urinary incontinence in adult females. We manufacture RADIESSE® and COAPTITE® at our facilities in Wisconsin, though we depend upon suppliers to manufacture components used in our products. We currently market our products through a dire...
Click here to read the whole Article (external link)

Bioform Medical Announces Earnings Call on November 2, 2009, and Presentation at Upcoming Investor Conference

Bioform Medical Announces Earnings Call on November 2, 2009, and Presentation at Upcoming Investor Conference - Yahoo! Finance.gnwlistitemmarginbottom {margin-bottom: 10.0px} .gnwtablebottommargin {margin-bottom: 10.0px} .gnwcellpaddingleft0 {padding-left: 0.0px} .gnwverticalaligntop {vertical-align: top} .gnwtextaligncenter {text-align: center} .gnwcellparagraphmargin {margin-bottom: 0px; margin-top: 0px} .gnwverticalalignbottom {vertical-align: bottom} .gnwwhitespacenowrap {white-space: nowrap} .gnwtextalignright {text-align: right} .gnwcellpaddingright0 {padding-right: 0.0px} .gnwunderlinestyle {text-decoration: underline} .gnwtextalignleft {text-align: left} .gnw_heading {font: 16px Arial; text-align: center} .gnw_subhead {font: 12px Arial; text-align: center} .gnw_colhead {font: 12px Arial; text-align: center} .gnw_colhead_uline {font: 12px Arial; text-align: center; border-bottom: solid black 1.0pt;} .gnw_colhead_dline {font: 12px Arial; text-align: center; border-bottom: double black 2.5pt;} .gnw_label {font: 12px Arial; vertical-align: bottom; text-align: left } .gnw_label_uline {font: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: solid black 1.0pt;} .gnw_label_uline_i10 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i15 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i20 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i25 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i30 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_dline {font: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: double black 2.5pt;} .gnw_label_i10 {font: 12px Arial; vertical-align: bottom; text-align: left; padding-left: 10.0px;} .gnw_label_i15 {font: 12px Arial; verti...
Click here to read the whole Article (external link)

BIOFORM MEDICAL INC Financials

Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...
Click here to read the whole Article (external link)

BioForm Medical Reports Financial Results for Quarter Ended September 30, 2009, First Quarter of Fiscal 2010

SAN MATEO, Calif., Nov. 2, 2009 (GLOBE NEWSWIRE) -- BioForm Medical, Inc. (Nasdaq:BFRM - News) today announced its financial results for the quarter ended September 30, 2009, which is the Company's first quarter of fiscal 2010. Net sales were $18.3 million for the quarter ended September 30, 2009 as compared to $15.7 million for the quarter ended September 30, 2008, an increase of $2.6 million or 16.6 %. The net loss was approximately $0.6 million for the quarter ended September 30, 2009 as compared to a net loss of $7.8 million for the quarter ended September 30, 2008. Cash and cash equivalents increased during the quarter by $0.7 million to $42.9 million at September 30, 2009. Operating Results: Domestic sales were $14.2 million for the quarter ended September 30, 2009 as compared to $12.8 million for the quarter ended September 30, 2008, an increase of $1.4 million or 10.9%. International sales were $4.1 million for the quarter ended September 30, 2009 as compared to $2.9 million for the quarter ended September 30, 2008, an increase of $1.2 million or 41.4%. Gross profit was $15.6 million for the quarter ended September 30, 2009 as compared to $12.9 million for the quarter ended September 30, 2008, an increase of $2.7 million, or 20.9%. As a percentage of sales, gross profit for the quarter ended September 30, 2009 was 85.3% as compared to 82.6% for the quarter ended September 30, 2008.Operating expenses were $16.0 million for the quarter ended September 30, 2009 as compared t...
Click here to read the whole Article (external link)

Kopin, Cardionet: Early Volume Plays

Stock quotes in this article: BEAT , KOPN , HBAN , ...
Click here to read the whole Article (external link)

BIOFORM MEDICAL INC Files SEC form 8-K, Results of Operations and Financial Condition

Show all filings for BIOFORM MEDICAL INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for BIOFORM MEDICAL INC 2-Nov-2009Results of Operations and Financial Condition Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purpose...
Click here to read the whole Article (external link)

BIOFORM MEDICAL INC Files SEC form 10-Q, Quarterly Report

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the federal securities laws. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those expressed or implied by such forward-looking statements. For a detailed discussion of these risks and uncertainties, see the "Risk Factors" section in Item 1A of Part II of this Form 10-Q. We caution the reader not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date of this Form 10-Q. We undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this Form 10-Q. Overview We are a medical aesthetics company focused on developing and commercializing products that are used by physicians to enhance the appearance of their patients. We were incorporated in Delaware in 1999 and commenced operations in 2000. From 2001 to 2003, we received certain U.S. and international regulatory clearances and approvals for, and engaged in commercial sales of, RADIESSE® and COAPTITE ®. We obtained FDA pre-market approval, or PMA, for our key commercial application of RADIESSE ® in December 2006. Our core product is RADIESSE®, an injectable dermal filler which is designed to provide long-lasting, cost-effective and safe aesthetic benefits for patients. We have also developed and commercialized COAPTITE®, an FDA approved tissue-bulking agent, which is marketed through our distribution agreement with Boston Scientific for use in the treatment of stress urinary incontinence in adult females. We manufacture RADIESSE® and COAPTITE® at our facilities in Wisconsin, though we depend upon suppliers to manufacture components used in our products. We currently market our products through a direct sales force of ...
Click here to read the whole Article (external link)

Bioform Medical upgraded by Piper Jaffray

Quotes for BFRM - Yahoo! Finance #screen,#masthead{text-align:center;margin:0;width:752px;} #screen.xpand,#masthead.xpand{width:100%;} #screen.xpand #yfncsubtit{width:100%;} #masthead{padding-bottom:12px;} #leftcol,#rightcol{margin:0;} #leftcol{width:155px;float:left;} #rightcol{width:585px;} #content{width:752px;} #footer {clear:both;} /*/*/ body{text-align:center;} #screen{text-align:left;min-width:700px;width:62.5em;width:expression( document.all.footer ? (document.all.footer.offsetWidth>1000) ? '980'+'px' : document.all.footer.offsetWidth :'62.5'+'em') ;margin:auto;border:1px solid #FFF;} #screen.xpand{width:100%; text-align:center} #portfolio{margin:10px auto;} #hdrads{margin:10px auto 0 auto;} #masthead,#leftcol,#rightcol{margin:0;} #masthead{width:100%;} #leftcol{float:left;width:18%;} #rightcol{float:right;width:80%;} #content{width:100%;} #footer{clear:both;text-align:center;padding:10px 0;width:60em;margin:auto;border:0px solid #FFF;} #leftNavTable,#yfncmh,#yfncmkttme,#yfncduplgnwrn,#yfncpsnlbar,#yfnctitbar,#y fncsubtit,#yfncbrobtn,#yfncsumtab, .yfnc_systitlelinea1,.yfnc_systitlelineb1,.yfnc_modtitlew1{ width:100%;} #yfncmh{width:100%;} .yfncsumdatagrid{background:#DCDCDC;width:100%;} .yfnc_modtitlew2{width:49%;} /**/ .yfncnhl{color:#666;margin-bottom:10px;} .yfncnhl .yfncnhlbl{color:#000;width:1.6em;text-align:center;} .yfncnhl .yfncnhltt{color:#000;width:50px;padding-top:2px;} .yfncnhltt { position: relative; } .yfncnhltt a { position: relative; display: block; /* opera */ width: 42px; height: 31px; } .yfncnhltt img { border: 0; } .yfncnhltt img.video_play { position: absolute; bottom: 2px; left: 2px; width: 13px; height: 14px; } #yfiunv table td, #yfiadvdec table td { width: 1%; } #yfiunv table td.name, #yfiadvdec table th.first, #yfiadvdec table td.first { width: 10%; white-space: normal; } #leftcol{display:none;} #rightcol{display:block;} ...
Click here to read the whole Article (external link)